Citations

Mayo Clinic

Clear

2716 citation(s) found for "Ma, Michelle".

A Disposable Tear Glucose Biosensor—Part 4
Belle, Jeffrey T. La , Engelschall, Erica, Lan, Kenneth, Shah, Pankti, Saez, Neil , Maxwell, Stephanie, Adamson, Teagan, Abou-Eid, Michelle, McAferty, Kenyon, Patel, Dharmendra, Patel, Dharmendra R., Cook, Curtiss B.

Journal of Diabetes Science and Technology | February 11, 2014 | Volume: 8 | Issue: 1 | Pages: 109-116

10.1177/1932296813511741 | PMID 24876546 Get It

Objective: A prototype tear glucose (TG) sensor was tested in New Zealand white rabbits to assess eye irritation, blood glucose (BG) and TG lag time, and correlation with BG. Methods: A total of 4 animals were used. Eye irritation was monitored by Lissamine green dye and analyzed using image analysis software. Lag time was correlated with an oral glucose load while recording TG and BG readings. Correlation between TG and BG were plotted against one another to form a correlation diagram, using a Yellow Springs Instrument (YSI) and self-monitoring of blood glucose as the reference measurements. Finally, TG levels were calculated using analytically derived expressions. Results: From repeated testing carried over the course of 12 months, little to no eye irritation was detected. TG fluctuations over time visually appeared to trace the same pattern as BG with an average lag times of 13 minutes. TG levels calculated from the device current measurements ranged from 4 to 20 mg/dL and correlated linearly with BG levels of 75-160 mg/dL (TG = 0.1723 BG = 7.9448 mg/dL; R 2 = .7544). Conclusion: The first steps were taken toward preliminary development of a sensor for self-monitoring of tear glucose (SMTG). No conjunctival irritation in any of the animals was noted. Lag time between TG and BG was found to be noticeable, but a quantitative modeling to correlate lag time in this study is unnecessary. Measured currents from the sensors and the calculated TG showed promising correlation to BG levels. Previous analytical bench marking showed BG and TG levels consistent with other literature.
Patient-Reported Quality of Supportive Care Among Patients With Colorectal Cancer in the Veterans Affairs Health Care System
Ryn, Michelle van , Arora, Neeraj, Jackson, George L., Zafar, S. Yousuf , Zullig, Leah L. , Provenzale, Dawn, Yeazel, Mark W. , Jindal, Rahul M. , Clauser, Steven B., van Ryn, Michelle, Phelan, Sean M. , Haggstrom, David Andrew , Griffin, Joan M. , van Ryn, Michelle

Journal of Clinical Oncology | February 4, 2014 | Volume: 32 | Issue: 8 | Pages: 809-815

10.1200/jco.2013.49.4302 | PMID 24493712 Get It

Purpose High-quality supportive care is an essential component of comprehensive cancer care. We implemented a patient-centered quality of cancer care survey to examine and identify predictors of quality of supportive care for bowel problems, pain, fatigue, depression, and other symptoms among 1,109 patients with colorectal cancer. Patients and Methods Patients with new diagnosis of colorectal cancer at any Veterans Health Administration medical center nationwide in 2008 were ascertained through the Veterans Affairs Central Cancer Registry and sent questionnaires assessing a variety of aspects of patient-centered cancer care. We received questionnaires from 63% of eligible patients (N = 1,109). Descriptive analyses characterizing patient experiences with supportive care and binary logistic regression models were used to examine predictors of receipt of help wanted for each of the five symptom categories. Results There were significant gaps in patient-centered quality of supportive care, beginning with symptom assessment. In multivariable modeling, the impact of clinical factors and patient race on odds of receiving wanted help varied by symptom. Coordination of care quality predicted receipt of wanted help for all symptoms, independent of patient demographic or clinical characteristics. Conclusion This study revealed substantial gaps in patient-centered quality of care, difficult to characterize through quality measurement relying on medical record review alone. It established the feasibility of collecting patient-reported quality measures. Improving quality measurement of supportive care and implementing patient-reported outcomes in quality-measurement systems are high priorities for improving the processes and outcomes of care for patients with cancer.
CALR mutation studies in chronic neutrophilic leukemia
Elliott, Michelle A. , Pardanani, Animesh , Tefferi, Ayalew , Lasho, Terra L.

American Journal of Hematology | January 13, 2014 | Volume: 89 | Issue: 4 | Pages: 450-450

10.1002/ajh.23665 | PMID 24421250 Get It

Efficacy of Continuous Glucose Monitoring in Improving Glycemic Control and Reducing Hypoglycemia: A Systematic Review and Meta-Analysis of Randomized Trials
Gandhi, Gunjan Y. , Kovalaske, Michelle A., Kudva, Yogish C. , Walsh, Kristin Harris, Elamin, Mohamed B., Beers, M Claire, Coyle, Cathy, Goalen, Melissa, Murad, Mohammad Safwan, Erwin, Patricia J., Corpus, Joshua, Montori, Víctor M. , Murad, M. Hassan , Goalen, Melissa J., Murad, M Hassan , Montori, Victor M

Journal of Diabetes Science and Technology | January 10, 2014 | Volume: 5 | Issue: 4 | Pages: 952-965

10.1177/193229681100500419 | PMID 21880239 Get It

Objective: We conducted a systematic review and meta-analysis to assess the efficacy of continuous glucose monitoring (CGM) in improving glycemic control and reducing hypoglycemia compared to self-monitored blood glucose (SMBG). Methods: We searched MEDLINE, EMBASE, Cochrane Central, Web of Science, and Scopus for randomized trials of adults and children with type 1 or type 2 diabetes mellitus (T1DM or T2DM). Pairs of reviewers independently selected studies, assessed methodological quality, and extracted data. Meta-analytic estimates of treatment effects were generated using a random-effects model. Results: Nineteen trials were eligible and provided data for meta-analysis. Overall, CGM was associated with a significant reduction in mean hemoglobin A1c [HbA1c; weighted mean difference (WMD) of −0.27% (95% confidence interval [CI] −0.44 to −0.10)]. This was true for adults with T1DM as well as T2DM [WMD −0.50% (95% CI −0.69 to −0.30) and −0.70 (95% CI, −1.14 to −0.27), respectively]. No significant effect was noted in children and adolescents. There was no significant difference in HbA1c reduction between studies of real-time versus non-real-time devices (WMD −0.22%, 95% CI, −0.59 to 0.15 versus −0.30%, 95% CI, −0.49 to −0.10; p for interaction 0.71). The quality of evidence was moderate due to imprecision, suggesting increased risk for bias. Data for the incidence of severe or nocturnal hypoglycemia were sparse and imprecise. In studies that reported patient satisfaction, users felt confident about the device and gave positive reviews. Conclusion: Continuous glucose monitoring seems to help improve glycemic control in adults with T1DM and T2DM. The effect on hypoglycemia incidence is imprecise and unclear. Larger trials with longer follow-up are needed to assess the efficacy of CGM in reducing patient-important complications without significantly increasing the burden of care for patients with diabetes.
Glycemic Control in the Medical Intensive Care Unit
Kovalaske, Michelle A., Gandhi, Gunjan Y.

Journal of Diabetes Science and Technology | January 10, 2014 | Volume: 3 | Issue: 6 | Pages: 1330-1341

10.1177/193229680900300613 | PMID 20144387 Get It

Hyperglycemia in the critically ill is a well-known phenomenon, even in those without known diabetes. The stress response is due to a complex interplay between counter-regulatory hormones, cytokines, and changes in insulin sensitivity. Illness/infection, overfeeding, medications (e.g., corticosteroids), insufficient insulin, and/or volume depletion can be additional contributors. Acute hyperglycemia can adversely affect fluid balance (through glycosuria and dehydration), immune and endothelial function, inflammation, and outcome. While there are several insulin infusion protocols that are able to safely and effectively treat hyperglycemia, the bulk of accumulated evidence does not support a causal relationship between acute hyperglycemia and adverse outcomes in the medical intensive care unit. Meta-analysis of randomized controlled trials suggests there is no benefit to tightening glucose control to normal levels compared to a reasonable and achievable goal of 140 to 180 mg/dl. There is a significantly increased risk of hypoglycemia. Although there is some evidence that patients without known diabetes have worse outcomes than those with known diabetes, more recent evidence is conflicting. Glycemic control in critically ill patients should not be neglected, as studies have not tested tight versus no/poor control, but tight versus good control. A moderate approach to managing critical illness hyperglycemia seems most prudent at this juncture. Future research should ascertain whether there are certain subgroups of patients that would benefit from tighter glycemic goals. It also remains to be seen if tight glucose control is beneficial once hypoglycemia is minimized with technological advances such as continuous glucose monitoring systems.
Thyroid Hormone-Responsive Pituitary Hyperplasia Independent of Somatostatin Receptor 2
Brinkmeier, Michelle L. , Stahl, Justin H., Gordon, David F. , Ross, Brian D. , Sarapura, Virginia D. , Dowding, Janet M., Lloyd, Ricardo V., Ridgway, E. Chester, Camper, Sally A. , Kendall, Susan K.

Molecular Endocrinology | January 8, 2014 | Volume: 15 | Issue: 12 | Pages: 2129-2136

10.1210/mend.15.12.0744 | PMID 11731614 Get It

AbstractMice homozygous for the targeted disruption of the glycoprotein hormone α-subunit (αGsu) display hypertrophy and hyperplasia of the anterior pituitary thyrotropes. Thyrotrope hyperplasia results in tumors in aged αGsu−/− mice. These adenomatous pituitaries can grow independently as intrascapular transplants in hypothyroid mice, suggesting that they have progressed beyond simple hyperplasia. We used magnetic resonance imaging to follow the growth and regression of thyrotrope adenomatous hyperplasia in response to thyroid hormone treatment and discovered that the tumors retain thyroid hormone responsiveness. Somatostatin (SMST) and its diverse receptors have been implicated in cell proliferation and tumorigenesis. To test the involvement of SMST receptor 2 (SMSTR2) in pituitary tumor progression and thyroid hormone responsiveness in αGsu−/− mutants, we generated Smstr2−/−, αGsu−/− mice. Smstr2−/−, αGsu−/− mice develop hyperplasia of thyrotropes, similar to αGsu−/− mutants, demonstrating that SMSTR2 is dispensable for the development of pituitary adenomatous hyperplasia. Thyrotrope hyperplasia in Smstr2−/−, αGsu−/− mice regresses in response to T4 treatment, suggesting that SMSTR2 is not required in the T4 feedback loop regulating TSH secretion.
Thyroid Hormone Is Essential for Pituitary Somatotropes and Lactotropes*
Stahl, Justin H., Brinkmeier, Michelle L. , Greco, T. L. , Watkins‐Chow, Dawn E. , Campos‐Barros, Ángel , Lloyd, Ricardo V., Camper, Sally A. , Kendall, Susan K.

Endocrinology | January 8, 2014 | Volume: 140 | Issue: 4 | Pages: 1884-1892

10.1210/endo.140.4.6627 | PMID 10098528 Get It

Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study
Mielke, Michelle M. , Savica, Rodolfo , Wiste, Heather J. , Weigand, Stephen D. , Vemuri, Prashanthi , Lowe, Val J. , Roberts, Rosebud O., Geda, Yonas E. , Petersen, Ronald C. , Knopman, David S. , Machulda, Mary M. , Jack, Clifford R. , Mielke, Michelle M , Vemuri, Prashanthi , Geda, Yonas E

Neurology | December 27, 2013 | Volume: 82 | Issue: 1 | Pages: 70-76

10.1212/01.wnl.0000438229.56094.54 | PMID 24371306 Get It

Implicit and explicit weight bias in a national sample of 4,732 medical students: The medical student CHANGES study
Dovidio, John F. , Puhl, Rebecca M. , Nelson, David , Yeazel, Mark W. , Perry, Sylvia , Ryn, Michelle van , Phelan, Sean M. , Burgess, Diana Jill , Hardeman, Rachel R. , Perry, Sylvia P , van Ryn, Michelle

Obesity | December 23, 2013 | Volume: 22 | Issue: 4 | Pages: 1201-1208

10.1002/oby.20687 | PMID 24375989 Get It

ObjectiveTo examine the magnitude of explicit and implicit weight biases compared to biases against other groups; and identify student factors predicting bias in a large national sample of medical students.MethodsA web‐based survey was completed by 4,732 1st year medical students from 49 medical schools as part of a longitudinal study of medical education. The survey included a validated measure of implicit weight bias, the implicit association test, and 2 measures of explicit bias: a feeling thermometer and the anti‐fat attitudes test.ResultsA majority of students exhibited implicit (74%) and explicit (67%) weight bias. Implicit weight bias scores were comparable to reported bias against racial minorities. Explicit attitudes were more negative toward obese people than toward racial minorities, gays, lesbians, and poor people. In multivariate regression models, implicit and explicit weight bias was predicted by lower BMI, male sex, and non‐Black race. Either implicit or explicit bias was also predicted by age, SES, country of birth, and specialty choice.ConclusionsImplicit and explicit weight bias is common among 1st year medical students, and varies across student factors. Future research should assess implications of biases and test interventions to reduce their impact.
Developing novel blood‐based biomarkers for Alzheimer's disease
Snyder, Heather M. , Carrillo, María C. , Henriksen, Kim , Jeromin, Andreas, Lovestone, Simon , Mielke, Michelle M. , O’Bryant, Sid E. , Sarasa, M., Sj⊘gren, Magnus, Soares, Holly , Teeling, Jessica L. , Trushina, Eugenia , Ward, Malcolm , West, Tim , Bain, Lisa J. , Shineman, Diana W., Weiner, Michael W. , Fillit, Howard , Grodstein, Francine , Mielke, Michelle M , Trushina, Eugenia , O'Bryant, Sid

Alzheimer's & Dementia | December 21, 2013 | Volume: 10 | Issue: 1 | Pages: 109-114

10.1016/j.jalz.2013.10.007 | PMID 24365657 Get It

AbstractAlzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant discussion, including potential next steps to move this area of research forward.